Conference Reports for NATAP

Back

Conference on Retroviruses and Opportunistic Infections Denver, CO, United States February 22 - 25, 2026     New HIV Drug Development   Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026 - (03/09/26)   A new one-a-day-pill holds promise for HIV's 'forgotten population' - (03/04/26)   Managing Complex Antiretroviral Regimens, Switch BIC/LEN Commentary - (03/02/26)   Phase 3 Efficacy and Safety of Switch From Complex Regimen to Single-Tablet BIC/LEN in ARTISTRY-1 - (02/26/26)   Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial - (02/26/26)   ViiV HEALTHCARE PRESENTS PIPELINE DATA FOR TWO INVESTIGATIONAL HIV TREATMENT THERAPIES WITH POTENTIAL FOR TWICE-YEARLY DOSING - (02/27/26)   Injectable HIV-1 Capsid Inhibitor VH4011499 (VH-499) Formulation Supports Ultra-Long-Acting - (02/27/26)   Pharmacokinetics and Evaluation of Potential Dosing Regimens for Long-Acting VH4524184 - (02/27/26)   Maintenance of HIV Suppression at 12 Months With Lotivibart (VH3810109, N6LS) Q4M + CAB LA QM: The EMBRACE Study - (02/27/26)   Safety, Pharmacokinetics, and Antiviral Activity of GS-3242, a Novel Long-Acting Injectable INSTI - (02/26/26)   Nonclinical Pharmacology of GS-3242, a Novel Long-Acting INSTI in Clinical Development - (02/23/26)   Nonclinical Pharmacokinetics of a Novel INSTI GS-3242 Supports a Human Long-Acting Injectable - (02/23/26)   Twice-Yearly Lenacapavir, Teropavimab, and Zinlirvimab for HIV-1: 52 Week Resistance Analysis - (02/23/26)   Patient-Reported Outcomes After 52 Weeks of Twice-Yearly Lenacapavir, Teropavimab, and Zinlirvimab - (02/23/26)   Dose Selection of Ultra-Long-Acting Cabotegravir as HIV-1 Pre-Exposure Prophylaxis: A Phase 1 Study - (02/23/26)   Third-Generation INSTI VH4524184 (VH-184) Has an Enhanced Resistance Profile vs Bictegravir - (02/23/26)   Population PK and Exposure-Response Analysis of Orally Administered VH4011499 in People With HIV-1 - (02/23/26)   Switch to BIC + LEN in Virologically Suppressed People With HIV on Complex Regimens: Week 96 Outcomes - (02/23/26)   Phase 3 Efficacy and Safety of Switch From B/F/TAF to Single-Tablet BIC/LEN in ARTISTRY-2 - (02/23/26)   Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People with HIV-1 at 96 Weeks - (02/23/26)   Once-Weekly Islatravir Plus Lenacapavir Maintains HIV-1 Suppression Through 96 Weeks: Phase 2 Study - (02/24/26)   Switch to DOR/ISL (100/0.25 mg) QD From Oral ART: Week 96 Update From an Open-Label Phase 3 Study - (02/23/26)   Switch to DOR/ISL (100/0.25 mg) QD from BIC/FTC/TAF: 96-Week Update from a Blinded Phase 3 Study - (02/23/26)   Efficacy and Safety of Doravirine/Islatravir (100/0.25 mg) in Adults with HIV and Renal Impairment - (02/23/26)   Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options - (02/22/26)   ViiV HEALTHCARE SHOWCASES LONG-ACTING HIV INNOVATION AND POTENTIAL OF ULTRA LONG-ACTING PIPELINE, INCLUDING NEW DATA FOR FIRST THIRD-GENERATION INTEGRASE INHIBITOR AT CROI 2026 - (02/22/26)   Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy - (02/26/26)   DOR/ISL (100/0.25 mg) vs BIC/FTC/TAF for Initial HIV-1 Therapy: Week 48 Results of a Phase III Study - (02/26/26)   ART HIV Treatment   The Impact of SEARCH Community Precision Health on HIV Incidence in Rural Kenya and Uganda - (03/12/26)   Impact of U.S. Funding Shifts on HIV Care: A Rapid Survey of Clinics and Programs in 32 Countries - (03/11/26)   Week-24 Outcomes of Long-Acting Injectable ART in People With HIV and Suboptimal Viral Suppression - (03/11/26)   Hepatitis B Reactivation/Infection in People With HIV on Tenofovir-Sparing Antiretroviral Therapy - (03/11/26)   Longitudinal Enrollment and Churn in the AIDS Drug Assistance Program in 3 States, 2014-2021 - (03/11/26)   Outcomes Initiate CAB+RPV LA in OPERA h Viral Loads >50 vs.≥50 vs. <50 copies/mL<50 copies/mL - (03/09/26)   Virologic Outcomes After LA ART Initiation With and Without Viremia in 2 Large US Clinic Cohorts - (03/09/26)   Long-Acting Cabotegravir and Rilpivirine: Real World Outcomes at 3 Years. ANRS CO3 AquiVIH-NA Cohort - (03/09/26)   Clinical Outcomes among Patients on Injectable CAB/RPV With and Without Viremia at 8 US Clinics - (03/09/26)   bNAb Sensitivity Does Not Fully Explain Post-Treatment Control in Early HIV-Treated Women During ATI - (03/07/26)   Early Switch to CAB+RPV LA in Treatment-Naive Adults With HIV-1: Month 11 Outcomes From VOLITION - (03/07/26)   The Potential Effect of Ending CDC Funding for HIV Tests: A Modeling Study in 25 US States - (03/05/26)   Meta-Analysis of DTG/3TC vs DTG 3DRs in ART-Naive People With High Baseline Viral Loads and Low CD4+ - (03/03/26)   Ibalizumab demonstrates real-world durability in people living with multi-drug resistant HIV - (03/03/26)   Lenacapavir Hyperstabilization of HIV Capsid Inhibits Infection of Resting and Activated CD4 T Cells - (03/02/26)   Long-Term Effectiveness of Lenacapavir in Heavily Treatment-Experienced People With HIV-1 in the US - (03/02/26)   HIV Incidence Could Rise by 73% in 30 States if Ryan White Ends: A Simulation Study - (03/02/26)   HIV Incidence Could Rise by 73% in 30 States if Ryan White Ends: A Simulation Study, Abstract - (03/02/26)   Long-Acting Cabotegravir+Rilpivirine in Adolescents: IMPAACT 2017 Week 96 & End of Study Results - (02/28/26)   Safety and Treatment Completion of 1HP Versus 3HP in People With HIV [on virally suppressed DTG]: The One-to-Three Trial - (02/28/26)   One-Month vs. 3-Month Rifapentine-Based Prophylaxis for Tuberculosis in People with HIV - (02/28/26)   Twice-Daily Dolutegravir With a 4-Month Rifapentine-Based Regimen for HIV-Associated Tuberculosis - (02/28/26)   HIV-1 Susceptibility to Lenacapavir Is Not Affected by Capsid Protein Polymorphisms T107A and T107S - (02/28/26)   Efficacy and Safety of B/F/TAF in Children and Infants Aged ≥1 Month, Weighing 3 to <25 kg: Week 24 - (02/28/26)   Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial - (02/27/26)   Phase 3 Efficacy and Safety of Switch From Complex Regimen to Single-Tablet BIC/LEN in ARTISTRY-1 - (02/27/26)   ViiV HEALTHCARE REPORTS POSITIVE 12-MONTH DATA SHOWING INVESTIGATIONAL BNAB LOTIVIBART (N6LS) MAINTAINS HIGH LEVELS OF VIRAL SUPPRESSION IN LONG-ACTING HIV TREATMENT REGIMEN - (02/27/26)   ViiV HEALTHCARE REPORTS LONG-ACTING INJECTABLE CABENUVA EFFECTIVELY MAINTAINS VIRAL SUPPRESSION IN ADOLESCENTS LIVING WITH HIV, WITH >97% PREFERRING INJECTIONS OVER DAILY ORAL TREATMENT - (02/27/26)   Safety and pharmacokinetics of long-acting cabotegravir and rilpivirine in young children 10 to <40 kg - (02/27/26)   DOLPHIN-Moms: Pharmacokinetics and HIV suppression with once-daily dolutegravir and 3HP in pregnancy - (02/26/26)   DOLPHIN-KIDS: Phase I/II Trial of Dolutegravir With 3HP for TB Prevention in Children With HIV - (02/26/26)   DTG/3TC is non-inferior to DTG-based 3-drug ART in children with HIV: D3/Penta 21 week 96 results - (02/26/26)   Aging, Comorbidities   Projecting State-Level Aging Patterns Among People with HIV in the United States - (03/09/26)   Longitudinal Associations of Semaglutide with Liver Fibrosis Score in People with HIV - (03/11/26)   Cell type-specific mitochondrial function and T cell dynamics in people with and without HIV - (03/10/26)   Mitochondrial DNA Copy Number and Cardiovascular-Kidney-Metabolic Syndrome in People with HIV - (03/10/26)   Change and Interaction Between Mitochondrial DNA Copy Number and Epigenetic After HIV Seroconversion - (03/10/26)   GLP-1 Receptor Agonists: Are They a Cure for Everything? - (03/10/26)   The GrimAge clock corresponds to accelerated brain aging and executive dysfunction in people with HIV - (03/10/26)   Neuropsychiatric Changes in People with HIV With or Without Long COVID After SARS-CoV-2 Infection - (03/09/26)   Kidney Function Decline Following COVID-19 Infection Among People with HIV - (03/09/26)   Emerging Non-AIDS Comorbidities Among Young Adults With and Without Perinatally-Acquired HIV - (03/09/26)   When I'm 64: Neurodegeneration, Epigenetic Aging, and Cognition in Older People With HIV - Alan Winston - (03/09/26)   When I'm 64: Neurodegeneration, Epigenetic Aging, and Cognition in Older People With HIV - Shibani Mukerji - (03/09/26)   Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026 - (03/09/26)   Initiating Semaglutide Therapy Reduces Tobacco Cigarette use among People with HIV - (03/07/26)   HIV can replicate in two cell types in the CNS suggesting multiple pathways to neurologic symptoms - (03/07/26)   Body Mass Index and Virologic Outcomes in Individuals on CAB+RPV LA in the OPERA Cohort - (03/07/26)   Tirzepatide use in People with HIV Shows Effectiveness for Weight Loss and Diabetic Control - (03/07/26)   Real-World Outcomes of Tirzepatide Use in People With HIV With and Without Diabetes - (03/07/26)   Evaluation of GLP-1 Medications in an Observational Cohort of People with HIV in Washington, DC (2011-2025) - (03/07/26)   Effects of Semaglutide on Subclinical Cardiovascular Health in People With HIV - (03/07/26)   APOBEC3 Signatures in HIV Reservoir Associate with Arterial Inflammation through Interferon Pathways - (03/07/26)   A Multimorbidity Model of HIV Disease Progression - (03/05/26)   The Grow Your Muscle (GYM) Study: A 48-Week Physical Activity RCT in PWH and PWOH With Sarcopenia - (03/05/26)   IMPROVING STEPS AND DIET QUALITY REDUCES SYMPTOMS IN ADULTS WITH HIV: RESULTS FROM PROSPER-HIV STUDY - (03/05/26)   Longitudinal Housing Instability & Frailty Incidence Among People with HIV - (03/05/26)   WALKING SPEED AS A KEY CORRELATE OF INFLAMMATION AND EPGENETIC AGEING IN OLDER ADULTS WITH HIV FUNCFRAIL STUDY - (03/04/26)   Cellular Senescence Impacts Both the Innate and Adaptive Immune System in Frail Men with HIV - (03/04/26)   Persistent GrimAge Acceleration and Telomere Attrition in HIV Elite Controllers - (03/04/26)   Cross-sectional and Longitudinal Effects of 3TC on Brain Integrity in Persons with HIV - (03/04/26)   Obesity measured at ART initiation and the risk of cardiovascular disease, cancer and death in people with HIV - (03/04/26)   Metabolic Dysregulation in HIV: T-Cell Aging Beyond Chronological Age - (03/04/26)   Single-Cell Multiomics Reveals Systemic Immune Aging Acceleration in People Living with HIV - (03/04/26)   Cellular Senescence Is Elevated in PWH and Reversed ex vivo by Dasatinib-Quercetin Senolytic Therapy - (03/04/26)   PRESENCE OF EXCESS VISCERAL ABDOMINAL FAT IMPACTS METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN PEOPLE WITH HIV - (03/03/26)   Cancer-related mortality in people with HIV (PWH) compared to the general population (2006-2023) - (03/03/26)   Cancer Survival Differences Persist Across Cancer Treatment Modalities Among People With HIV - (03/03/26)   Mitochondrial DNA Copy Number and Cardiovascular-Kidney-Metabolic Syndrome in People with HIV - (03/03/26)   Early Nephrology Care and Poverty among People Living with HIV and End-Stage Kidney Disease - (03/03/26)   High Baseline Prevalence and Suboptimal Control of Hypertension in the REPRIEVE Trial - (03/02/26)   Cancer Incidence and Risk Factors Among People with HIV in REPRIEVE - (03/02/26)   Modifiable Factors Could Mitigate Greater Burden of Brain Small Vessel Injury in Women with HIV - (03/01/26)   Depression and HIV-Disease Duration Differentially Affect Subcortical Brain Regions in PWH - (03/01/26)   MASH and the Progression of Cognitive Decline in Older People With HIV: A Prospective Study - (03/01/26)   Kidney Function Decline Following COVID-19 Infection Among People with HIV - (03/01/26)   Chronic Cannabis Use is Associated with Faster Epigenetic Aging in People with HIV - (03/01/26)   The GrimAge clock corresponds to accelerated brain aging and executive dysfunction in people with HIV - (03/01/26)   Neurocognitive Decline in PWH with Virological Response Versus Controls: the ANRS 0093s Aging HAND Study - (03/01/26)   Food Insecurity [nutritious foods] is Associated with increased Frailty Prevalence among People with HIV - (03/01/26)   Hypertension Risk in a Large Cohort of People Living With HIV After a Switch to Dolutegravir - (03/01/26)   Association of HIV Reservoir with Subclinical Myocardial Dysfunction in People with HIV - (03/01/26)   Impact of Substance Use on Viral Reservoir and Immune Cell Gene Expression in People With HIV on ART - (03/01/26)   Changes in Weight and Glycemia After Integrase Inhibitor Initiation in People with HIV and Diabetes - (03/01/26)   Body Roundness Index and Incident Diabetes and Hypertension Among People with and at Risk for HIV - (03/01/26)   Incident Hypertension After Switching to Integrase Strand Transfer Inhibitors-Based ART, RESPOND Cohort - (03/01/26)   Two Years of Dolutegravir (DTG) Use Did Not Affect Body Composition in People Without HIV Infection - (03/01/26)   NNRTI-to-INSTI Switches Across North America May Have Had a Substantial Population Impact on Weight - (03/01/26)   Brain Structural And Functional Changes After Antiretroviral Therapy Initiation In People With HIV - (02/27/26)   Population-level obesity trends by HIV status in the pre/post DTG era in the SEARCH study in rural East Africa - (02/27/26)   Prevalence and long-term transitions of cardiovascular-kidney-metabolic syndrome stages in PWH - (02/27/26)   The Impact of Semaglutide on Depressive Symptoms Among People With HIV - (02/27/26)   Metabolic Syndrome and Cognitive Impairment among Men with and without HIV - (02/27/26)   Rates and Risk Factors for Oropharyngeal Squamous Cell Carcinoma Among People Living With HIV - (02/26/26)   Incident Hypertension in REPRIEVE: Risk Factors, Pitavastatin Effect & Cardiovascular Consequences - (02/25/26)   Relationship of Inflammatory, Cardiac and Lipid Biomarkers to Cardiovascular Events in REPRIEVE - (02/25/26)   PrEP, Prevention   Beating the Clock: Timing 10E8.4/iMab Administration to Block SHIV Infection - (03/10/26)   National LAI-PrEP Use and Retention in Care in the United States, 2022-2024 - (03/09/26)   Prior PrEP Use and Discontinuation in Individuals Newly Diagnosed with HIV Infection, London, UK - (03/05/26)   Prescriptions for Oral vs Injectable HIV Preexposure Prophylaxis, 2012-2025 - (03/05/26)   Declining HIV Incidence and Differential PrEP Effectiveness Among Key Populations With STIs, 2014-25 - (03/02/26)   HIV Incidence in a Nationwide Cohort of Transgender Women in the United States and Puerto Rico - (03/01/26)   Long term use, HIV testing and effectiveness in individuals on CAB LA PrEP in the Trio Health Cohort - (03/01/26)   Real-World Medication Use and Potential Interactions With Lenacapavir for HIV PrEP - (03/01/26)   Expected Impact of Twice-yearly Lenacapavir on PrEP Coverage Disparities and HIV Incidence in the US - (03/01/26)   Partner Acquisition Rate by HIV Testing and Treatment Engagement: A Multicountry Analysis - (03/01/26)   Stigma and PrEP use among transgender women under differing state LGBTQ healthcare policies - (03/01/26)   Comparing Behavioral and Socio-Structural Exposures for Women's HIV Prevention in the Urban South - (03/01/26)   Trends in Long-Acting PrEP Awareness, Willingness, and Uptake Among Men Who Have Sex With Men - (03/01/26)   Adherence and Persistence in US Real-World New PrEP Users: Cabotegravir (CAB-LA) vs Oral PrEP - (03/01/26)   EBONI M12 Results: High Real-World Effectiveness and Acceptance of CAB LA for PrEP in Black Women - (03/01/26)   Cabotegravir LA for PrEP: Progress in HIV Prevention from Three Years of OPERA Data - (03/01/26)   Injection-Site Reactions More Common and Bothersome With Single Doses of Lenacapavir vs Cabotegravir - (03/01/26)   Implants releasing NRTTI MK-8591 fail to protect macaques against SHIV containing the M184V mutation - (03/01/26)   Safety and Antiviral Effect of 10E8.4/ibalizumab in People With HIV: A Phase 1b Trial - (03/01/26)   Ultra-Long-Acting MPT Injectable with Dolutegravir and Levonorgestrel for HIV PrEP and Contraception - (02/28/26)   Once-Yearly Lenacapavir for PrEP: Model-Informed Dose Determination and Phase 3 Trial Design - (02/28/26)   BIC/FTC/TAF for PEP: Completion, Tolerability, and Transition to PrEP in a Real-World Cohort - (02/28/26)   Comparing PrEP Coverage and HIV Acquisition Between CAB LA and Oral PrEP in the OPERA Cohort - (02/28/26)   Final Results of the ANRS Prevenir Study with Daily or On Demand Oral PrEP with TDF/FTC in Paris, France - (02/24/26)   MK-8527 Phase 3 Dose Selection for Monthly Oral HIV-1 Pre-exposure Prophylaxis - (02/24/26)   Twice-Yearly Subcutaneous Lenacapavir for PrEP: Updated HIV-1 Incidence & Safety Data in PURPOSE 1 at the End of the Randomized Blinded Phase - (02/24/26)   Resistance Analysis of the PURPOSE Studies Through the End of the Randomized Blinded Phase - (02/24/26)   Lenacapavir for PrEP: HIV-1 Incidence and Safety from PURPOSE 2 at the End of Randomized Blinded Phase - (02/24/26)   Hepatitis, Liver Disease   Simple Adiposity Measures Identify MASLD in People with HIV: Results from a US Multicenter Cohort - (03/07/26)   Effect of DTG/3TC vs. BIC/FTC/TAF on Steatotic Liver Disease: 96-week Analysis of PASO-DOBLE Trial - (03/07/26)   Elevated Triglyceride and Ceramide Metabolites in MASLD among PWH - (03/07/26)   Prevalence and Risk Factors for Steatotic Liver Disease in PWH with Resolved HCV - (03/07/26)   Long-Term Outcomes of Liver Transplant Recipients Living With HIV: A Multicenter Case-Control Study - (03/05/26)   Reducing ED HCV Confirmatory Test Turnaround Time Through Point-of-Care Implementation - (03/05/26)   Point-of-Care HCV RNA Compared to Laboratory-Based HCV RNA in a Tribal Health Setting - (03/04/26)   HIV Status Drives Distinct Immune Pathways of Persistent Portal Hypertension After HCV Cure - (03/04/26)   Baseline Plasma and T-cell Immune Profiles Linked to Liver Stiffness Regression After HCV Cure - (03/04/26)   Glecaprevir/Pibrentasvir Combination Within Individual Particles Drives Optimal LAI Performance - (03/04/26)   VRON-0200 Induced Broad and Sustained Anti-HBV Immunity in Chronically HBV-Infected Patients - (02/28/26)   Efficacy and Safety of Long-Term Bulevirtide in Chronic Hepatitis Delta: Final Results From the Phase 3 MYR301 Study, Including 2 Participants With HIV/HBV/HDV Coinfection - (02/26/26)   Progressing towards global hepatitis C elimination: a systematic review and meta-analysis of care cascades in key populations - (02/26/26)   "Cure", Viral Control   bNAb Sensitivity Continuously Enhances Immune Response in an HIV Dynamics Model - (03/10/26)   Fc/CD16 Interaction Is the Major Contributor to ADCC of HIV-Infected CD4 T Cells - (03/10/26)   Refractory HIV-Expressing CD4+ T Cells Retain Infectivity After NNRTI-Induced CARD8 Activation - (03/10/26)   Bispecific Biologics That Target and Activate the HIV Latent Reservoir Ex Vivo and In Vivo - (03/10/26)   Effect of the TKI Dasatinib in SAMHD1, HIV Reservoir and Senescence in ART-Treated PWH (BCN04-DASA) - (03/07/26)   The role of gut bacteria-specific CD4+ T cells in HIV persistence during ART - (03/07/26)   CROI: bNAb Sensitivity Does Not Fully Explain Post-Treatment Control in Early HIV-Treated Women During ATI - (03/07/26)   Decoding the Somatic Mutation Landscape in Persisting HIV-1 Infected CD4+ T Clones - (03/07/26)   CARD8 Activation for Reservoir Reduction with Efavirenz (CARRE Trial) An open-label, single arm trial to assess the safety and efficacy of in vivo CARD8 activation with Efavirenz intensification on HIV-1 reservoir reduction in people living with HIV-1 - (03/07/26)   AUTOLOGOUS NEUTRALISING ANTIBODIES AND EFFECTIVE CD8 T-CELLS MAINTAIN HIV POST-INTERVENTION CONTROL - (03/05/26)   Altered Viral Kinetics at ATI After Dual LS-bNAbs Plus ART: A Preliminary Analysis of RIO Arm B - (03/05/26)   A phase 1 trial of N-803 with or without dual bNAbs to achieve ART-free viral control: ACTG A5386 - (03/05/26)   Immune-Mediated Viral Control With Budigalimab ± Trosunilimab: First Results of Phase II Global RCT - (03/02/26)   CROI: Very-Early ART-Initiation Associated with Sustained Aviremia in Time-To-Rebound Pediatric ATI - (03/01/26)   Viral Control among Children in Botswana Receiving Combination Broadly Neutralizing Antibodies - (02/28/26)   CD4-Targeted IL-15 Enhanced bNAb Activity and Improved SHIV Control After Treatment Interruption - (02/26/26)   Safety and Viral Kinetics of Analytical Treatment Interruption in PWH in a Large Phase 2 Global RCT - (02/27/26)   Immune-Related AEs After Low-Dose, Finite-Duration Budigalimab ± Trosunilimab in People With HIV - (02/27/26)   Repeated IL-10/PD-1 Blockades Potently Control SIV Rebound and Limit Reservoir in the Absence of ART - (02/27/26)